Emerging role of gefitinib in the treatmentof non-small-cell lung cancer (NSCLC)

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 81-98

  Tiseo, M ^a   Bartolotti, M ^a   Gelsomino, F ^a   Bordi, P ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

EGFR; Gefitinib; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASIAN; ASTHENIA; BLOOD DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EGFR GENE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; GENE; GENE MUTATION; GERIATRIC PATIENT; HEMATOLOGIC DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SMOKING; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VOMITING; ARTICLE; CLINICAL TRIAL; GENETICS; LUNG TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; QUINAZOLINES;

EID: 77957030888     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/dddt.s6594     Document Type: Review

References (79)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics,2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathologyand genetics of tumors of the lung, pleura, thymus and heart. In:Kleihues P, Sobin LH, editors. WHO Classification of Tumors. Lyon:IARC press; 2004.
3. Non Small Cell Lung Cancer Collaborative Group. Chemotherapyin non-small cell lung cancer: a meta-analysis using update dataon individual patients from 52 randomised clinical trials. BMJ.1995;311(7010):899-909.
4. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition tosupportive care improves survival in advanced non-small-cell-lung cancer:a systematic review and meta-analysis of individual patients data from16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617-4625.
5. Waters JS, O'Brien MER. The case for the introduction of new chemotherapyagents in the treatment of advanced non-small cell lungcancer in the wake of the findings of The National Institute of ClinicalExcellence (NICE). Br J Cancer. 2002;87(5):481-490.
6. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trialcomparing three platinum-based doublets in advanced non-small-celllung cancer. J Clin Oncol. 2002;20(21):4285-4291.
7. Schiller JH, Harrington D, Belani CP, et al. Comparison of fourchemotherapy regimens for advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2002;346(2):92-98.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone orwith bevacizumab for non-small-cell lung cancer. N Engl J Med.2006;355(24):2542-2550.
9. Reck M, Von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plusgemcitabine with either placebo or bevacizumab as first-line therapy fornon-squamous Non-Small-Cell Lung Cancer: AVAiL. J Clin Oncol.2009;27(14):1227-1234.
10. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparingcisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551.
11. Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatmentof advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(4):430-440.
12. Azzoli CG, Baker S Jr, Temin S, et al. American Society of ClinicalOncology clinical practice guideline update on chemotherapy for stage IVnon-small-cell lung cancer. J Clin Oncol. 2009;27(36):6251-6266.
13. Bunn PA Jr, Franklin W. Epidermal Grow Factor receptor expression,signal pathways, and inhibitors in non-small cell lung cancer. SeminOncol. 2002;29 Suppl 14:S38-S44.
14. AstraZeneca, Macclesfield, UK. Data on file 2009.
15. Albanell JR, Rojo F, Averbuch S, et al. Pharmacodynamic studies ofthe epidermal growth factor receptor inhibitor ZD1839 in skin fromcancer patients: histopatologic and molecular consequences of receptorinhibition. J Clin Oncol. 2002;20(1):110-124.
16. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetics trialof the selective oral epidermal growth factor receptor tyrosine kinaseinhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solidmalignant tumors. Ann Oncol. 2003;14(6):922-930.
17. Haura EB, Sommers E, Backer A, et al. Pilot phase II study ofpreoperativegefitinib in early stage non small cell lung cancer withassessment of intra-tumor gefitinib levels and tumor target modulation[abstract]. J Clin Oncol. 2007;25 Suppl:S18.
18. McKillop D, McCormick AD, Millar A, et al. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica. 2005;35(1):39-50.
19. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orallyactive inhibitor of epidermal growth factor signaling with potential forcancer therapy. Cancer Res. 2006;62(20):5749-5754.
20. Di Gennaro E, Barbarino M, Bruzzese F, et al. Critical role of bothp27KIP1 and p21CIP1/WAF1 in the anti-proliferative effect ofZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinaseinhibitor, in head and neck squamous carcinoma cell. J Cell Physiol.2003;195(1):139-150.
21. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation andgefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2004;96(15):1133-1141.
22. Ciardiello F, Kuroda J, Puthalakath H, et al. Inhibition of growth factorproduction and angiogenesis in human cancer cells by ZD1839 (Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001;7(5):1459-1465.
23. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic,and pharmacodynamic trial of ZD1839, a selective oral epidermalgrowth factor receptor tyrosine kinase inhibitor, in patients with fiveselected solid tumor types. J Clin Oncol. 2002;20(21):4292-4302.
24. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oralepidermal growth factor receptor-tyrosine kinase inhibitor, is welltolerated and active in patients with solid, malignant tumors: results ofa phase I trial. J Clin Oncol. 2002;20(9):2240-2250.
25. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oralepidermal growth factor receptor tyrosine kinase inhibitor ZD1839is generally well-tolerated and has activity in non-small-cell lungcancer and other solid tumors: results of a phase I trial. J Clin Oncol.2002;20(18):3815-3825.
26. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomizedphase II trial of gefitinib for previously treated patients withadvanced non-small-cell lung cancer. J Clin Oncol. 2003;21(12):2237-2246.
27. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitorof the epidermal growth factor receptor tyrosine kinase, in symptomaticpatients with non-small-cell lung cancer. A randomized trial. JAMA.2003;290(16):2149-2158.
28. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportivecare in previously treated patients with refractory advanced nonsmall-cell lung cancer: results from a randomised, placebo-controlled,multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet.2005;(366):1527-1537.
29. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) inpatients of Asian origin with refractory advanced non-small celllung cancer: subset analysis from the ISEL study. J Thorac Oncol.2006;1(8):847-855.
30. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib inpreviously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
31. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors ofoutcome with gefitinib in a phase III placebo-controlled study in advancednon-small-cell lung cancer. J Clin Oncol. 2006;24(31):5034-5042.
32. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer -molecularand clinical predictors of outcome. N Engl J Med. 2005;353(2):133-144.
33. Zhu C-Q, da Cunha Santos G, Ding K, et al. Role of KRAS andEGFR as biomarkers for response to erlotinib in National CancerInstitute of Canada Clinical Trials Group study BR-21. J Clin Oncol.2008;26(26):4268-4275.
34. Cufer T, Vrdoljak E, Gaafar R, et al. Phase II, open-label, randomizedstudy (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as secondlinetherapy in patients with advanced (stage IIIB or IV) non-small-celllung cancer. Anticancer Drugs. 2006;17(4):401-409.
35. Kim ES, Hirsch V, Mok T, et al. Gefitinib versus docetaxel in previouslytreated non-small-cell lung cancer (INTEREST): a randomized phaseIII trial. Lancet. 2008;(372):1809-1818.
36. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32,of gefitinib versus docetaxel in previously treated Japanese patients withnon-small-cell lung cancer. J Clin Oncol. 2008;26(26):4244-4252.
37. Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinibversus docetaxel in non-small cell lung cancer patients who havepreviously received platinum-based chemotherapy. Clin Cancer Res.2010;16(4):1307-1314.
38. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcomewith gefitinib and docetaxel in previously treated non-small-celllung cancer: data from the randomized phase III INTEREST Trial.J Clin Oncol. Epub 2009 Dec 28.
39. Shepherd FA, Douillard J, Fukuoka M et al. Comparison of gefitiniband docetaxel in patients with pretreated advanced non-small cell lungcancer (NSCLC): Meta-analysis from four clinical trials [abstract]. J Clin Oncol. 2009;27 Suppl:S15.
40. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combinationwith gemcitabine and cisplatin in advanced non-small-cell lung cancer:A phase III trial - INTACT 1. J Clin Oncol. 2004;22(5):777-784.
41. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combinationwith paclitaxel and carboplatin in advanced non-small-cell lung cancer:A phase III trial - INTACT 2. J Clin Oncol. 2004;22(5):785-794.
42. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiationof cytotoxic drugs activity in human cancer cells by ZD-1839(Iressa), an epidermal growth factor receptor-selective tyrosine kinaseinhibitor. Clin Cancer Res. 2000;6(5):2053-2063.
43. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trialof erlotinib hydrochloride (OSI-774) combined with carboplatin andpaclitaxel chemotherapy in advanced non-small-cell lung cancer. J ClinOncol. 2005;23(25):892-899.
44. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study oferlotinib in combination with cisplatin and gemcitabine in advancednon-small-cell lung cancer: the Tarceva Lung Cancer InvestigationTrial. J Clin Oncol. 2007;25(12):1545-1552.
45. Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbinein chemotherapy-naïve elderly patients with advanced non-small-celllung cancer (INVITE) a randomized, phase II study. J Clin Oncol.2008;26(26):4253-4260.
46. Goss G, Ferry D, Laurie S, et al. Randomized phase II study of gefitinibcompared with placebo in chemotherapy-naïve patients with advancednon-small-cell lung cancer and poor performance status. J Clin Oncol.2009;27(13):2253-2260.
47. Argiris A, Mittal N. Gefitinib as first-line, compassionate use therapyin patients with advanced non-small cell lung cancer. Lung Cancer.2004;43(3):317-322.
48. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermalgrowth factor receptor underlying responsiveness of non-smallcelllung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.
49. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:Correlation with clinical response to gefitinib therapy. Science.2004;(304):1497-1500.
50. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations arecommon in lung cancers from "never smokers" and are associated withsensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A.2004;101(36):13306-13311.
51. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact ofepidermal growth factor receptor mutation in non - small-cell lung cancerpatients treated with gefitinib. J Clin Oncol. 2005;23(11):2493-2501.
52. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermalgrowth factor receptor gene predict prolonged survival after gefitinibtreatment in patients with non-small-cell lung cancer with post-operativerecurrence. J Clin Oncol. 2005;23(11):2513-2520.
53. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptorgene mutations and increased copy numbers predict gefitinib sensitivityin patients with recurrent non-small-cell lung cancer. J Clin Oncol.2005;23(28):6829-6837.
54. Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factorreceptor activating mutations in Spanish gefitinib-treated non-small-celllung cancer patients. Ann Oncol. 2005;16(7):1081-1086.
55. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosinekinase domain of the epidermal growth factor receptor are associatedwith improved survival in gefitinib-treated chemo-refractory lungadenocarcinomas. Clin Cancer Res. 2005;11(16):5878-5885.
56. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib asfirst-line therapy for advanced non-small-cell lung cancer with epidermalgrowth factor receptor mutations. Br J Cancer. 2006;95(8):998-1004.
57. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study ofgefitinib for chemotherapy naive patients with advanced non-small-celllung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24(21):3340-3346.
58. Yang C, Yu C, Shih J, et al. Specific EGFR mutations predict treatmentoutcome of stage IIIB/IV patients with chemotherapy-naive non-smallcelllung cancer receiving first-line gefitinib monotherapy. J Clin Oncol.2008;26(16):2745-2753.
59. Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patientswith advanced non-small-cell lung cancer harboring somatic EGFRmutations. J Clin Oncol. 2008;26(15):2442-2449.
60. Inoue A, Kobayashi K, Usui K, et al. First-line Gefitinib for patientswith advanced non-small-cell lung cancer harbouring epidermal growthfactor receptor mutations without indication for chemotherapy. J ClinOncol. 2009;27(9):1394-1400.
61. Sutani A, Nagai Y, Udagawa K, et al. Gefitinib for non-small-cell lungcancer patients with epidermal growth factor receptor gene mutationsscreened by peptide nucleic acid-locked nucleic acid PCR clamp. Br JCancer. 2006;95(11):1483-1489.
62. Yoshida K, Yatabe Y, Park JY, et al. Prospective validation of predictionof gefitinib sensitivity by epidermal growth factor receptor genemutation in patients with non-small cell lung cancer. J Thorac Oncol.2007;2(1):22-28.
63. Sunaga N, Tomizawa Y, Yanagitani N, et al. Phase II prospective studyof the efficacy of gefitinib for the treatment of stage III/IV non-smallcell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer. 2007;56(3):383-389.
64. Tamura K, Okamoto I, Kashii T, et al. Multicentre prospectivephase II trial of gefitinib for advanced non-small cell lung cancerwith epidermal growth factor receptor mutations: results of the WestJapan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer.2008;98(5):907-914.
65. Sugio K, Uramoto H, Onitsuka T, et al. Prospective phase II study ofgefitinib in non-small cell lung cancer with epidermal growth factorreceptor mutations. Lung Cancer. 2009;64(3):314-318.
66. Cappuzzo F, Ligorio C, Jänne PA, et al. Prospective study of gefitinibin epidermal growth factor receptor fluorescence in situ hybridizationpositive/phospho-Akt-positive or never smoker patients with advancednon small-cell lung cancer: The ONCOBELL trial. J Clin Oncol.2007;25(16):2248-2255.
67. West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advancedbronchioloalveolar carcinoma: Southwest Oncology Group StudyS0126. J Clin Oncol. 2006;24(12):1807-1813.
68. Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy ofadvanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res. 2005;11(8):3032-3037.
69. Mok T, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin/paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
70. Lee JS, Park K, Kim SW, et al. A randomized phase III study of gefitinib(IRESSATM) versus standard chemotherapy (gemcitabine pluscisplatin) as a first-line treatment for never-smokers with advancedor metastatic adenocarcinoma of the lung [abstract]. J Thor Oncol.2009;4 Suppl:PRS.4.
71. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plusdocetaxel in patients with non-small-cell lung cancer harboring mutationsof the epidermal growth factor receptor (WJTOG3405): an openlabel, randomized phase 3 trial. Lancet Oncol. Epub 2009 Dec 21.
72. Kobayashi K, Inoue A, Maemondo M, et al. First-line gefitinib versusfirst-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL)in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations:A phase III study (002) by North East Japan Gefitinib Study Group[abstract]. J Clin Oncol. 2009;27 Suppl:S15.
73. Takeda K, Hida T, Sato T, et al. Randomized phase III trial ofplatinum-doublet chemotherapy followed by gefitinib comparedwith continued platinum-doublet chemotherapy in Japanese patientswith advanced non-small-cell lung cancer: results of a West JapanThoracic Oncology Group Trial (WJTOG0203). J Clin Oncol. Epub2009 Dec 28.
74. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenanceGefitinib or placebo after concurrent chemoradiotherapy and docetaxelconsolidation in inoperable stage III non-small-cell lung cancer: SWOGS0023. J Clin Oncol. 2008;26(15):2450-2456
75. Ochs JS. Rationale and clinical basis for combining gefitinib (IRESSA,ZD1839) with radiation therapy for solid tumors. Int J Radiat OncolBiol Phys. 2004;58(3):941-949.
76. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lungdisease and predictive factors for tumor response in patients withadvanced non-small cell lung cancer treated with gefitinib. Lung Cancer.2004;45(1):93-104.
77. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors forinterstitial lung Disease, antitumor response, and survival in nonsmall-cell lung cancer patients treated with gefitinib. J Clin Oncol.2006;24(16):2549-2556.
78. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvementin symptoms and quality of life for patients with non-small-celllung cancer receiving gefitinib in a randomized controlled trial. J ClinOncol. 2005;23(13):2946-2954.
79. Sekine I, Ichinose Y, Nishiwaki Y, et al. Quality of life and disease-relatedsymptoms in previously treated Japanese patients with nonsmall-cell lung cancer: results of a randomized phase III study (V-15-32)of gefitinib versus docetaxel. Ann Oncol. 2009;20(9):1483-1488.